 "Sun Pharma Advanced Research Q1 loss at Rs 9.74 crore")
The company had posted a net profit of Rs 9.51 crore during the same period of the previous fiscal, Sun Pharma Advanced Research Company Ltd (SPARC) said in a statement.
Total income of the company during the April-June quarter declined marginally to Rs 35.85 crore. It was Rs 35.67 crore in the same period of the last fiscal.
Also Read
SPARC spent Rs 27.23 crore on clinical trials and professional charges during the quarter under review as against Rs 7.82 crore in the same period last fiscal.
Shares of SPARC were trading at Rs 171.05 per share on the BSE during the afternoon trade, down 2.65 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%